T
Tianjin COSYCHEM Technology
A national high-tech enterprise integrating technical services
About Tianjin COSYCHEM Technology
Established in October 2010, Tianjin COSYCHEM Technology Co., Ltd. operates as a pivotal supplier of chemical raw materials for the life sciences sector. The company, founded by Song Yanmin, has strategically positioned itself within China's biopharmaceutical landscape. After more than a decade of technological development, COSYCHEM has built a comprehensive business model that encompasses specialized pharmaceutical intermediates, raw materials for diagnostic analytics, and components for nucleic acid drugs.
The firm functions as a Contract Development and Manufacturing Organization (CDMO), providing integrated services from research and development to production for life science enterprises. Its operations are centered around multiple technology platforms, including synthetic technology, gene therapy delivery, nucleic acid drug discovery, and in-vitro diagnostics (IVD) services. The company's revenue is generated through the sale of its products and its CRO and CDMO services. COSYCHEM serves a client base primarily composed of pharmaceutical and life science companies.
COSYCHEM's product portfolio is extensive, featuring core materials for both in-vitro diagnostics and nucleic acid therapeutics. Key offerings include a delivery system for small nucleic acid drugs, known as GALNAc, and the capability to produce phosphoramidite monomers in multi-kilogram quantities. The company has also developed a cationic lipid library to create LNP delivery systems for gene therapy applications. To bolster its research capabilities, the company has forged strategic partnerships, establishing a joint laboratory for nucleic acid drug innovation with Peking University Health Science Center and a genomic nucleic acid technology platform with Nankai University. These collaborations are intended to advance the downstream application of nucleic acid drugs and vaccines.
Financially, the company has demonstrated significant growth, securing over RMB 200 million in financing over three years and completing a Pre-B round exceeding CNY 100 million in May 2024. This capital is earmarked for the commercial expansion of its biological technology chemical raw materials and their applications in nucleic acid drugs and IVD. COSYCHEM holds over 50 independent intellectual property rights and has received numerous national-level recognitions, including being named a National High-tech Enterprise and a National Recognized "Little Giant" Enterprise.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | May 2024 | $14M | $55M | Cohesive Energy Investment | ↗ |
| EARLY VC✓Equity / VC | Sep 2022 | $14M | $55M | Tianchuang Venture Capital · Binhai Capital | ↗ |
Growth signals
Latest recorded traffic for Tianjin COSYCHEM Technology is 440 monthly website visits, down 70.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tianjin COSYCHEM Technology in the Binhai New Area ecosystem
The Tianjin COSYCHEM Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- TCTianchuang Venture Capital
Binhai Capital- CICohesive Energy Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tianjin COSYCHEM Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tianjin COSYCHEM Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









